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Sir,
The New Delhi metallo-b-lactamase (NDM-1) was initially identi-
fied in Escherichia coli and Klebsiella pneumoniae isolates in
Sweden, from a patient previously hospitalized in India.1 To
date, NDM producers in Latin America have been scarce, and asso-
ciated with species of Enterobacteriaceae from Guatemala,
Mexico, Colombia and Brazil, although in Honduras it was reported
in Acinetobacter baumannii.2 – 6 Here, we report two genetically
unrelated NDM-1-producing Acinetobacter pittii isolates identified
in Paraguay.
Since 1996, the Pan American Health Organization (PAHO) has
supported a regional surveillance system, the Antimicrobial
Resistance Surveillance Network in Latin America (ReLAVRA),
that includes 794 laboratories from 20 Latin American countries,
including their respective reference laboratories.7 This network
provides reliable, timely and reproducible microbiological data in
order to improve patient care. A regional protocol for the detection
of carbapenemases has been harmonized and implemented
through ReLAVRA. Briefly, metallo-b-lactamase (MBL) production
is suspected in isolates that exhibit decreased susceptibility to car-
bapenems (CLSI criteria) and a positive synergy test result
between a disc containing 10 mg of imipenem and a disc contain-
ing 750 mg of EDTA plus 1900 mg of sodium thioglycolate.8
During 2012, following the ReLAVRA algorithm, the National
Health Laboratory of Paraguay confirmed an MBL phenotype
in two Acinetobacter spp. isolates recovered from a single
hospital. This phenotype had not previously been observed in
Acinetobacter spp. from Paraguay. The first case was a 7-year-old
patient admitted in July because of acute encephalitis. After
2 months of hospitalization, an Enterobacter cloacae extended-
spectrum b-lactamase producer and Acinetobacter M15274
were recovered from the CSF obtained through a ventricular
shunt. The patient received multiple treatment regimens, includ-
ing trimethoprim/sulfamethoxazole, ciprofloxacin and amikacin,
which resulted in clinical and microbiological cure. The patient
died after 4 months of hospitalization due to non-infectious
causes. The second case was a 2-year-old patient with a diagnosis
of acute lymphocytic leukaemia who was admitted in November.
Two weeks later the patient developed sepsis, and Acinetobacter
M15373 was isolated from a blood culture. The patient showed
clinical improvement after treatment with meropenem plus ami-
kacin and was discharged alive after 50 days. Both patients were
hospitalized in the same oncology ward but 4 months apart from
each other. Remarkably, the patients had no history of travelling.
Strains were submitted to the Regional Reference Laboratory
(Servicio Antimicrobianos, INEI, ANLIS ‘Dr Carlos G. Malbrán’) for
further characterization. Strains were identified as A. pittii by
matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF; Bruker, Germany); the 10 most prob-
able database matches were all consistent with A. pittii.
Antimicrobial susceptibility testing revealed an identical resist-
ance profile in both A. pittii isolates, except for ampicillin/sulbac-
tam and quinolones (Table 1). EDTA reduced the carbapenem
MICs by at least three dilutions in both strains, suggesting
the presence of MBLs (Table 1). The modified Hodge test gave
negative results with meropenem but was positive (weakly) with
imipenem.
In both isolates, PCR screening followed by DNA sequencing de-
tected the presence of blaNDM-1. PCRs targeting other b-lactamase
genes (blaVIM, blaIMP, blaSPM, blaKPC, blaOXA-23, blaOXA-24/40, blaOXA-48,
blaOXA-51, blaOXA-58, blaOXA-143, blaCTX-M, blaSHV and blaTEM) were
negative. Sequencing of a 2.5 kb fragment surrounding blaNDM-1
from both strains revealed 100% identity to the sequence
reported for Acinetobacter lwoffii, where ISAba125 was located
upstream of blaNDM-1, followed by DtrpF and tat.
9,10 The genes
that follow to the 3′ end, DgroES, groEL, ISCR27 and the second
ISAba25 were PCR mapped, revealing a Tn125 composite trans-
poson as previously reported in A. pittii.11
ApaI PFGE studies revealed that the A. pittii isolates were
not clonally related (.10 bands of difference in the macro-
restriction pattern). Multilocus sequence typing (MLST) was per-
formed according to the MLST Database (http://www.pasteur.fr/
recherche/genopole/PF8/mlst/). M15274 and M15373 displayed
unique and novel sequence types (STs), designated ST320 and
ST321, respectively. M15274 and M15373 shared only the rplB
allele, confirming that they were genetically unrelated. Further-
more, these STs branched with other reported isolates belonging
to the A. pittii genomic species, confirming the MALDI-TOF results.
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The blaNDM-1 gene was transferred by biparental conjugation
to either sodium azide-resistant E. coli J53 or A. baumannii
ATCC 19606 from M15373 but not from M15274, conferring
non-susceptibility to carbapenems on the recipient strain
(Table 1). S1 nuclease digestion showed that both A. pittii and
the transconjugant strains harboured a single plasmid of
54 kb that hybridized with the blaNDM probe. Plasmids gave
negative results for all the Inc groups when assessed by PCR rep-
licon typing.12
Additionally, further characterization of 23 contemporary
carbapenem-resistant Acinetobacter spp. isolated in the same
institution from November 2012 to March 2013 (clinical strains
and patient swab samples) revealed a lack of MBL production
and matched A. baumannii by MALDI-TOF.
A. pittii has recently been recognized as a key organism for the
dissemination of NDM, since it has been associated with the dis-
persal of this carbapenemase in such diverse scenarios as food of
animal origin and sewage, and has been responsible for both
sporadic human infection and large outbreaks in hospital
units.10,13,14 Until now, non-baumannii Acinetobacter spp. expres-
sing NDM have not been described in the American continent.
These A. pittii clinical isolates are the first characterized NDM-1
producers from Paraguay. The origin of NDM-1-positive A. pittii in
Paraguay remains unclear, since no history of travel to the sug-
gested reservoirs of NDM was established for either patient. Our
finding of blaNDM-1 on plasmids of identical 54 kb size in A. pittii
strains with a heterogeneous clonal background suggests that
blaNDM-1 most likely spread by the transfer of plasmids in A. pittii.
Recent published data suggest that A. pittii could act as a poten-
tial NDM reservoir for Enterobacteriaceae based on the ease of
plasmid transfer to E. coli,11 as observed in one of the isolates
reported here. Despite this ability, no further cases of NDM produ-
cers have so far been observed in the hospital.
In conclusion, the emergence of NDM in A. pittii constitutes a
public health concern in Latin America, highlighting the relevance
of an integrated surveillance of carbapenemase producers.
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Table 1. Antimicrobial susceptibility (MICs in mg/L)a of NDM-producing A. pittii clinical isolates and A. baumannii and E. coli transconjugant and recipient
strains













Imipenemc .256 .256 .256 1 0.25 0.06
Imipenem/EDTAd 0.12 0.12 0.25 0.12 0.25 0.06
Meropenemc .256 .256 .256 0.5 1 0.015
Meropenem/EDTAd 0.12 0.25 0.5 0.015 1 0.015
Ertapenemc .256 .256 .256 2 1 0.25
Ampicillin/sulbactam .16 4 .16 .16 ≤1 ≤1
Piperacillin/tazobactam .64 .64 .64 .64 8 ≤4
Aztreonamc 32 32 32 ≤0.03 32 ≤0.03
Cefotaximec .256 .256 .256 32 16 ≤0.015
Ceftazidimec .256 .256 .256 .256 8 ≤0.06
Cefepimec .256 .256 .256 16 16 0.015
Cefoxitin .32 .32 .32 .32 ≤8 ≤8
Gentamicin ≤1 ≤1 8 ≤1 8 ≤1
Amikacin ≤2 ≤2 ≤2 ≤2 ≤2 ≤2
Nalidixic acid 16 ≤2 4 ≤2 4 ≤2
Ciprofloxacin 1 ≤0.25 1 ≤0.25 1 ≤0.25
Trimethoprim/sulfamethoxazole ≤2 ≤2 .256 ≤2 .256 ≤2
Nitrofurantoin .256 .256 .256 ≤16 .256 ≤16
Colistin ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5
Tigecyclinec 0.06 0.06 0.25 0.25 0.015 0.015
aAntimicrobial susceptibility testing according to CLSI standards.
bTransconjugant strains of A. pittii M15373.
cMICs were determined using agar dilution; MICs of other antibiotics were determined using the Vitek 2C (AST-N082 card).
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